What does fair value adjustment, share-based liability mean?

Captures the periodic non-cash adjustment to the carrying value of liabilities related to share-based payment arrangements that are classified as liabilities rather than equity. Fluctuations in this metric are often driven by changes in the company's stock price or the underlying valuation of the awards. It provides insight into the volatility of compensation-related obligations that must be settled in cash or equivalent instruments.

BioCryst Pharmaceuticals BCRX Fair Value Adjustment, Share-Based Liability

Fair Value Adjustment, Share-Based Liability at other companies

Nuvalent, Inc.NUVL

-$2.57M-79.7%

Eos Energy Enterprises, Inc.EOSE

-$4.23M+28.7%

CytokineticsCYTK

-$1.6M-141%

Nuvalent, Inc.NUVL

-$2.57M-79.7%

CytokineticsCYTK

-$1.6M-141%

Hut 8 Mining Corp.HUT

-$661K-158%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:FairValueAdjustmentShareBasedLiability.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's fair value adjustment, share-based liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's fair value adjustment, share-based liability?: BioCryst Pharmaceuticals (BCRX) reported fair value adjustment, share-based liability of -$2.81M in Q1 2026.
What does fair value adjustment, share-based liability mean?: Captures the periodic non-cash adjustment to the carrying value of liabilities related to share-based payment arrangements that are classified as liabilities rather than equity. Fluctuations in this metric are often driven by changes in the company's stock price or the underlying valuation of the awards. It provides insight into the volatility of compensation-related obligations that must be settled in cash or equivalent instruments.